Viagra and Alzheimer’s Risk: What the Research Really Shows

Facebook ↗WhatsApp ↗

Originally published 2021-12-12.

Does Viagra lower the risk of Alzheimer’s disease? The honest answer is: possibly, a little, but nobody has shown that it does. A widely shared 2021 study found that people who used sildenafil, the active ingredient in Viagra, were diagnosed with Alzheimer’s far less often than similar people who did not. A much larger 2024 study of British men found a smaller link, and a 2022 analysis found no link at all over a short follow-up. None of this research can tell you that taking the pill will protect your brain.

Viagra and Alzheimer’s Risk: The 2021 Study and What Followed

Below we explain what the 2021 Cleveland Clinic research actually did, why the “70 percent” headline needs care, what later studies found, and what this means for anyone wondering whether to ask about the drug.

What the 2021 Cleveland Clinic study found

The paper appeared in the journal Nature Aging on 6 December 2021. A team led by Feixiong Cheng, a computational biologist at the Cleveland Clinic’s Genomic Medicine Institute, set out to find existing, already approved medicines that might be repurposed against Alzheimer’s disease.

Rather than starting with patients, they started with biology. The team built a large network map of genes and proteins linked to the two hallmark features of Alzheimer’s: sticky amyloid plaques that collect between nerve cells, and tangles of a protein called tau that form inside them. They then scored more than 1,600 drugs approved by the US Food and Drug Administration on how closely each one acts on that shared amyloid-and-tau network. Sildenafil came out as the strongest candidate.

Only then did they turn to real-world data. Using a US insurance claims database covering more than seven million people, they compared people who had been prescribed sildenafil with people taking other common medicines. Over six years of follow-up, sildenafil users were 69 percent less likely to receive an Alzheimer’s diagnosis than non-users. The gap held when they compared sildenafil users with people taking losartan, metformin, diltiazem or glimepiride, drugs used for blood pressure, diabetes and heart conditions.

According to the Cleveland Clinic’s announcement, the lower rate appeared both in people with coronary artery disease, high blood pressure or type 2 diabetes, which are all linked to dementia risk, and in people without those conditions.

The lab work behind the headline

The team also tested sildenafil on brain cells grown from stem cells donated by people with Alzheimer’s disease. In that dish model, the drug encouraged the growth of nerve cells and reduced the excess chemical tagging of tau, known as hyperphosphorylation, that is thought to drive tangle formation.

That is an encouraging sign that the drug touches the right biology. It is still a long way from evidence in living people. Many compounds that look promising in cells have failed once they reached human trials, and Alzheimer’s research has a particularly long list of such disappointments.

Why “70% lower risk” does not mean prevention

The claims analysis was observational. It recorded who happened to be prescribed sildenafil and who later received an Alzheimer’s diagnosis. That design can reveal patterns, but it cannot separate the drug’s effect from the kind of people who take it.

Men who are prescribed an erectile dysfunction drug may differ from other people in ways that also affect dementia risk. They may be healthier, more sexually active, more socially connected or more likely to see a doctor regularly. Someone in the very early stages of memory decline may also be less likely to seek a prescription for sexual function at all, which can make the drug look protective when the arrow actually points the other way. Researchers call this reverse causation.

Cheng himself was careful on this point. In the Cleveland Clinic’s release he said, “our findings only establish an association between sildenafil use and reduced incidence of Alzheimer's disease,” and the team announced plans for a mechanistic study and a phase II randomised trial to test cause and effect.

The relative figure also needs context. A 69 percent lower rate compares groups; it says nothing about how many people in each group developed the disease, or what any one person’s risk would be.

What later research found

In 2022, a smaller analysis that followed patients for less than two years reportedly found no sign that sildenafil was linked to fewer Alzheimer’s diagnoses. A short window like that may simply be too brief to show an effect on a disease that develops over many years, so it neither confirms nor rules out the earlier result.

The most substantial follow-up came in February 2024. A team led by Ruth Brauer, a pharmacoepidemiologist at University College London, published a study in Neurology using UK health records for nearly 270,000 men aged 40 and over who had just been diagnosed with erectile dysfunction. About half were prescribed a drug from the same family as sildenafil, known as PDE5 inhibitors. During follow-up, 1,119 of the men developed Alzheimer’s.

Men prescribed these drugs were 18 percent less likely to be diagnosed than men who were not. That is a real but far smaller difference than the 2021 figure. The link was stronger in men who received more than 20 prescriptions, and it was seen with sildenafil but not with the related drugs tadalafil and vardenafil. Importantly, the apparent benefit almost vanished when the researchers excluded men followed for less than three years, which hints that early, undiagnosed disease may explain part of the pattern.

The study included only men, relied on prescriptions rather than confirmed use, and was again observational. Brauer’s team called for a randomised trial that includes women.

How sildenafil works, and why it might affect the brain

Sildenafil belongs to a class of medicines called phosphodiesterase type 5, or PDE5, inhibitors. Pfizer chemists working at Sandwich in Kent first made it in 1989 while searching for a treatment for angina, the chest pain caused by poor blood flow to the heart. It did little for angina, but trial volunteers reported a striking side effect, and the US Food and Drug Administration approved it for erectile dysfunction on 27 March 1998. A low-dose version, sold as Revatio, is also used for pulmonary arterial hypertension.

By blocking PDE5, the drug relaxes the smooth muscle in blood vessel walls and lets more blood flow through. Researchers have suggested a few ways this could matter for the brain:

  • Blood flow. Better circulation in small brain vessels could support nerve cells, since vascular damage is a known contributor to dementia.
  • Tau and amyloid. The Cleveland Clinic network analysis and cell experiments point to direct effects on the proteins involved in Alzheimer’s.
  • Cell signalling. PDE5 inhibitors raise levels of a messenger molecule called cGMP, which plays a role in memory formation in animal studies.

All three remain hypotheses. None has yet been confirmed in a randomised trial in people.

Myths worth clearing up

“Viagra prevents Alzheimer’s”

No study has shown this. The evidence is a set of associations, and the best-sized one points to a modest difference that may partly reflect who takes the drug.

“Anyone can take it just in case”

Sildenafil is a prescription medicine with real side effects, including headache, flushing, indigestion, nasal congestion and changes in vision. It must not be combined with nitrates such as nitroglycerin, which are used for chest pain, because the pair can cause a dangerous fall in blood pressure. If you are curious whether it is appropriate for you, talk to a doctor.

“Nothing can lower dementia risk”

That is not true either. Alzheimer’s disease causes around 60 to 70 percent of dementia cases, and several risk factors are linked to it that people and their doctors can act on, including high blood pressure, diabetes, physical inactivity, smoking, depression, hearing loss and poor sleep. Managing those has far stronger support than any repurposed pill.

What this means for readers

Drug repurposing is a sensible strategy. Approved medicines already have long safety records, so if one turns out to help against Alzheimer’s, it could reach patients much faster than a brand-new compound. That is why sildenafil keeps attracting interest.

The research so far is a reason for a proper clinical trial, not a reason to change what you take. If the question of dementia risk worries you, or someone in your family, the most useful step is a conversation with a doctor about blood pressure, blood sugar, hearing, sleep and activity, the factors with the clearest evidence behind them.

Sources: Fang et al., Nature Aging (2021); Cleveland Clinic news release via EurekAlert!, December 2021; ScienceAlert, 8 February 2024, on Brauer et al., Neurology; Wikipedia: Sildenafil; Wikipedia: Alzheimer’s disease; original coverage by ScienceAlert (2021).

COMMENTS